以色列生物制药公司PolyPid Ltd.与美国Azurity制药公司已正式达成一项商业化合作协议，共同推进创新药物D-Plex100的市场推广。该药物主要用于预防手术后的切口感染。
根据协议条款，Azurity制药将获得D-Plex100在美国市场的独家商业化权利。PolyPid则保留该药物在全球其他地区的权益。双方将整合资源，加速该产品在目标市场的准入与应用。
D-Plex100是一种局部给药的缓释制剂，旨在降低外科手术后的感染风险。手术部位感染是常见的术后并发症，可能导致患者康复期延长、再住院率上升及医疗成本增加。该药物的开发针对这一未满足的临床需求。
此次合作有望借助Azurity制药在美国专科医药领域的商业化专长与渠道网络，提升D-Plex100的市场渗透速度。对于PolyPid而言，此举是其推进产品管线商业化的重要步骤。
双方未披露协议的具体财务条款，但表示合作将涵盖市场推广、分销及后续支持等全方位活动。该交易仍需满足惯例成交条件，预计将在未来数月内完成必要的监管备案程序。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.